Cardura Articles
Warning on ED drug-drug interactions
19 January 2009
Andrx to exit brand-drug business
10 January 2005
Approval letter for Pfizer's Cardura XL
28 June 2004
Cipla signs deal with IVAX affiliate
5 September 2001
Pfizer's UK cardiovascular patient initiative
12 July 2001
Cardura safety mulled by FDA panel
30 May 2001
Pfizer's Cardura "no better" than diuretic
16 March 2000
Generic nifedipine gets tentative FDA approval
29 March 1999
Sepracor losses grow but market keeps faith
22 February 1999
Sepracor tops analysts' biotech stocks
20 January 1999
"Extraordinary"Viagra Sales Lift Pfizer Earnings
10 July 1998
Pfizer Posts Double-Digit Sales & Earnings Growth
15 April 1998
Pfizer Invests $179.6 Million In UK Facility
11 December 1997
Pfizer Enters New Product Cycle With Strong Potential
7 August 1997
Pfizer's Good Volume Growth Marred By Strong $
17 July 1997
Pfizer Gets AAA Ranking From S&P
12 June 1997
Zocor "Will Be World's Top-Selling Drug In 2005"
13 January 1997
Net Income Rises 21% in 3rd Qtr At Pfizer
21 October 1996
US Drug Majors See 2nd-Half Double-Digit Growth
29 July 1996
US FDA Seeks Comments On Consumer Ad Labeling
27 May 1996
1st-Qtr Sales Driven By New Products At Pfizer
22 April 1996
World Markets: Cancer, Cardiovascular, Menopause
19 February 1996
Mixed Results For Q4 1995 From US Drug Majors
29 January 1996
Pfizer Presents Fertile Pipeline
6 November 1995
US 3rd Qrt Results: Strong Gains For Pfizer, Lilly
23 October 1995
Proscar Versus Hytrin And Cardura For BPH
11 September 1995
Doxazosin Of Use In Diabetics, Says Study
12 June 1995
Pfizer's Cardura Approved For BPH
13 February 1995
Pfizer: Record Number Of Drugs In Phases II & III
31 October 1994
Strong Gains By US Firms In 2nd Quarter
1 August 1994
CARDURA IN BPH
6 June 1994
PFIZER RESULTS
23 May 1994
CURRENCIES STILL A FACTOR IN US 1st QTR
2 May 1994
STRONG DOLLAR WEAKENS US 1993 RESULTS
31 January 1994
DRUG THERAPY FOR MILD HYPERTENSION FAVORED
16 August 1993
PFIZER "CONFIDENT" IN CHANGING ENVIRONMENT
3 May 1993
PFIZER CONSIDERS PRICE CUTS
29 March 1993
PFIZER "COMMITTED" TO HEALTH CARE AND R&D
8 March 1993
US NEW PRESCRIPTI0N DRUG SALES IN 1991
13 April 1992
Showing 1-49 of 49 articles
- 1
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
